Surprise suitor for Elan

Last week, Elan announced plans to launch new acquisitions; this week it has become the target of Royalty Pharma, a US specialist pharmaceutical investment vehicle. A deal would value the Dublin-based pharmaceutical business at $6.6bn, and catches Elan at a moment of weakness. Lex's Stuart Kirk and Vincent Boland consider whether shareholders will be attracted by the offer.